GCAN Stock Overview
Engages in the development and commercialization of cannabinoid therapeutics. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
The Greater Cannabis Company, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.00045 |
| 52 Week High | US$0.0013 |
| 52 Week Low | US$0.0004 |
| Beta | 1.66 |
| 11 Month Change | 0% |
| 3 Month Change | -25.00% |
| 1 Year Change | -52.63% |
| 33 Year Change | -86.76% |
| 5 Year Change | -98.57% |
| Change since IPO | -99.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| GCAN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 0.5% |
| 1Y | -52.6% | 13.1% | 30.7% |
Return vs Industry: GCAN underperformed the US Pharmaceuticals industry which returned 14.2% over the past year.
Return vs Market: GCAN underperformed the US Market which returned 32.3% over the past year.
Price Volatility
| GCAN volatility | |
|---|---|
| GCAN Average Weekly Movement | 34.0% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GCAN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: GCAN's weekly volatility has increased from 26% to 34% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1 | Aitan Zacharin | www.gcanrx.com |
The Greater Cannabis Company, Inc. engages in the development and commercialization of cannabinoid therapeutics. It offers an oral transmucosal patch platform, which provides loaded actives absorbed by the buccal mucosa into the body. The company has a license agreement with Shaare Zedek Scientific Ltd.
The Greater Cannabis Company, Inc. Fundamentals Summary
| GCAN fundamental statistics | |
|---|---|
| Market cap | US$362.09k |
| Earnings (TTM) | -US$182.55k |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.0x
P/E RatioIs GCAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GCAN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$5.00k |
| Gross Profit | -US$5.00k |
| Other Expenses | US$177.55k |
| Earnings | -US$182.55k |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00023 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -54.1% |
How did GCAN perform over the long term?
See historical performance and comparison